Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

All You Need To Know About Switching, Spacing Covid Vaccine Doses

All You Need To Know About Switching, Spacing Covid Vaccine Doses

All COVID-19 vaccines approved, so far, are designed to teach the immune system to recognise and defend against the virus with a first dose, and then provide a second booster dose to reinforce that lesson.

Britain and other nations are considering ways to stretch scarce supplies of COVID-19 vaccines, including by delaying second doses, reducing dose sizes and switching vaccine types between the first and second shots.

The proposals have generated fierce debate among scientists. The following is the rationale behind, and criticism of, these alternative strategies:

Why delay the second dose?


In clinical trials, companies tested specific doses of their vaccines at precise time intervals to generate evidence showing how well they work. All COVID-19 vaccines approved, so far, are designed to teach the immune system to recognise and defend against the virus with a first dose, and then provide a second booster dose to reinforce that lesson.

Faced with surging pandemic and new, more transmissible coronavirus variants, some countries are hoping to broaden immunisation by giving some protection to as many people as possible with a first dose, and delaying second doses.

Maximising the number of people who have partial immunity "should reduce the number of severe COVID-19 cases and thus alleviate the burden on hospitals", said Michael Head, a global health expert at Britain's University of Southampton.

What about switching between COVID-19 vaccines?


Mixing or switching between COVID-19 vaccines is largely driven by the same aim - vaccinating as many people as possible as the pandemic still rages.

Giving a priming dose of one vaccine and a booster dose of another offers flexibility to offer whichever shots are available, rather than holding shots back so individuals always get both doses of the same vaccine.

Have these strategies been tested in rigorous trials?


No.

None of the late-stage COVID-19 vaccine trials compared these dose-sparing strategies or the effects of mixing vaccine types, said Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine (LSHTM).

Officials have cited limited evidence from trials that the Pfizer/BioNTech, the Oxford University/AstraZeneca and the Moderna vaccines all confer some protection against COVID-19 after the first dose.

Britain's MHRA health regulator on December 30 said it had found an 80 per cent effectiveness rate for the Oxford/AstraZeneca vaccine when two full doses are administered three months apart, higher than the average that the developers themselves had found.

A day later, the UK government's vaccine advisory committee said the Pfizer/BioNTech vaccine conferred 89 per cent protection from two weeks after the first dose, and that for the Oxford/AstraZeneca vaccine "the evidence shows that the initial dose ... offers as much as 70 per cent protection against the effects of the virus". It did not give detailed data.

Moderna reported its vaccine was 80 per cent protective after one dose, with efficacy peaking two weeks after the first shot.

There is no long-term evidence that any of these vaccines will offer lasting immunity based on just one dose, or how effective they will be if the second dose is delayed.

BioNTech and Pfizer warned on Monday they had no evidence their vaccine would continue to be protective if the second dose was given more than 21 days after the first.

Ideally, "it is safest and most cautious" to use vaccines in conditions exactly matching those of their trials, Evans said, but added: "In the real world, this is never so."

Dr. Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, told CNN on Friday the United States was unlikely to delay giving second doses.

"We're going to keep doing what we're doing," he said.

Likewise, scientists have raised concerns over the idea of mixing two different types of vaccines. Some experts speculate that, because all of the vaccines target the same outer "spike" protein of the virus, they could work together to train the body to fight off the virus.

There is no evidence this approach will work.

"There is literally zero data. It has not been tested, or if it has been tested, the data have not been made available," said John Moore, a professor of microbiology and immunology at Weill Cornell Medical College in New York.

What about reducing the amount of vaccine in each dose?


In the United States, some health officials are considering offering half doses of Moderna's vaccine to individuals aged 18 to 55. There is some clinical trial data backing this strategy.

Moncef Slaoui, chief adviser to the U.S. Operation Warp Speed vaccine programme , told CBS on Sunday that evidence from a Moderna trial showed the half dose induced an "identical immune response" to the higher 100 microgram dose in adults aged 55 and under. He said the US government was discussing the issue with Moderna and regulators.

Slaoui said he believed injecting half of the volume of vaccine was "a more responsible approach that would be based on facts and data".

Several US scientists agreed, but noted the data was not publicly available. "It's very fuzzy. I want to see that data," said Eric Topol, a genomics expert and director of the Scripps Research Translational Institute in La Jolla, California.

Moderna Chief Executive Stephane Bancel said on Tuesday he does not believe existing data from trials on the efficacy of a half-dose version would be sufficient to convince regulators, doctors or governments to approve such a move. "That data has not been published yet. It will be soon," Bancel said at a Goldman Sachs event.

"I don't see a world where that data is enough to convince the medical community, the (Vaccines and Related Biological Products Advisory Committee) and of course the agency (U.S. Food and Drug Administration), to move to 50 micrograms at this stage," he said.

So are these strategies safe? and will they work?


It is not clear.

While there is no scientific evidence on the impact of delaying COVID-19 vaccine doses, some experts believe it could be safe to wait, and the potential payoff in protecting a larger swath of the population may be worth it.

Others are not so sure.

"There's just no data," said Ian Jones, a professor of virology at Britain's Reading University.

The British Society of Immunology said in a statement on Monday that delaying a second dose by eight weeks "would be unlikely to have a negative effect on the overall immune response". It added that it would not expect any extra safety risks from the delay beyond the potential increased risk of contracting the disease during the gap between doses.

Some scientists also said that while there was no evidence to support the strategy of mixing vaccine doses from different manufacturers - a method known as heterologous prime-boost - evidence from other vaccines provided some reassurance.

"Based on previous studies which combine different vaccine types, a combination of the AstraZeneca and Pfizer vaccines is likely to be safe," said Helen Fletcher, a professor of immunology at LSHTM.

Topol, however, called the mix-and-match strategy "a big mistake" with "unpredictable" results - including the potential for adverse reactions or a significant dropoff in efficacy. "It makes no sense whatsoever," he said.

Some worry about safety issues, particularly with delaying the second dose for several weeks. The gap could allow time for the virus to evolve and develop resistance to the vaccine.

Weak antibody protection could also increase the risk of an abnormal immune response - such as antibody-dependent enhancement - when people encounter the real virus, Topol said.

How practical is it to prolong dosing schedules?


Extending the interval poses adherence risks, raising the chance people may forget or fail to return for a second dose.

It also increases the length of time during which they are less than optimally protected. And it could make it harder for health authorities to keep track of who has had which vaccine, when, and how often.

Given these risks, immunology and public health experts say clear communication is imperative to ensure people understand that although dosing schedules may be subject to change, two COVID-19 vaccine doses are needed to give the best protection.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
Elon Musk Unveils Grokipedia: An AI-Driven Alternative to Wikipedia
Russia’s President Putin Declares Burevestnik Nuclear Cruise Missile Ready for Deployment
US Administration Under President Donald Trump Reportedly Lifts Ban on Ukraine’s Use of Storm Shadow Missiles Against Russia
White House Announces No Imminent Summit Between Trump and Putin
China Presses Netherlands to “properly” Resolve the Nexperia Seizure as Supply Chain Risks Grow
Merz Attacks Migrants, Sparks Uproar, and Refuses to Apologize: “Ask Your Daughters”
Apple Challenges EU Digital Markets Act Crackdown in Landmark Court Battle
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
“Firepower” Promised for Ukraine as NATO Ministers Meet — But U.S. Tomahawks Remain Undecided
The Sydney Sweeney and Jeans Storm: “The Outcome Surpassed Our Wildest Dreams”
Dutch Government Seizes Chipmaker After U.S. Presses for Removal of Chinese CEO
AI and Cybersecurity at Forefront as GITEX Global 2025 Kicks Off in Dubai
Ex-Microsoft Engineer Confirms Famous Windows XP Key Was Leaked Corporate License, Not a Hack
Hungarian Prime Minister Viktor Orbán stated that Hungary will not adopt the euro because the European Union is falling apart.
Mayor in western Germany in intensive care after stabbing
Australian government pays Deloitte nearly half a million dollars for a report built on fabricated quotes, fake citations, and AI-generated nonsense.
BYD’s UK Sales Soar Nearly Nine-Fold, Making Britain Its Biggest Market Outside China
Latvia to Bar Tourist and Occasional Buses to Russia and Belarus Until 2026
Wave of Complaints Against Apple Over iPhone 17 Pro’s Scratch Sensitivity
Munich Airport Reopens After Second Drone Shutdown
Pro Europe and Anti-War Babiš Poised to Return to Power After Czech Parliamentary Vote
Sean ‘Diddy’ Combs Sentenced to Fifty Months in Prison Following Prostitution Conviction
Altman Says GPT-5 Already Outpaces Him, Warns AI Could Automate 40% of Work
Russian Research Vessel 'Yantar' Tracked Mapping Europe’s Subsea Cables, Raising Security Alarms
Global Cruise Industry Posts Dramatic Comeback with 34.6 Million Passengers in 2024
U.S. Demands Brussels Scrutinize Digital Rules to Prevent Bias Against American Tech
Private Equity’s Fundraising Surge Triggers Concern of European Market Shake-Out
Tokyo’s Jimbōchō Named World’s Coolest Neighbourhood for 2025
European Officials Fear Trump May Shift Blame for Ukraine War onto EU
The Personality Rights Challenge in India’s AI Era
Italy Considers Freezing Retirement Age at 67 to Avert Scheduled Hike
Italian City to Impose Tax on Visiting Dogs Starting in 2026
Study Finds No Safe Level of Alcohol for Dementia Risk
Trump Says Ukraine Can Fully Restore Borders with NATO Backing
Europe Signals Stronger Support for Taiwan at Major Taipei Defence Show
Germany Weighs Excluding France from Key European Fighter Jet Programme
Cyberattack Disrupts Check-in and Boarding Systems at Major European Airports
Björn Borg Breaks Silence: Memoir Reveals Addiction, Shame and Cancer Battle
When Extremism Hijacks Idealism: How the Baader-Meinhof Gang Emerged and Fell
JWST Data Brings TRAPPIST-1e Closer to Earth-Like Habitability
Trump Orders $100,000 Fee on H-1B Visas and Launches ‘Gold Card’ Immigration Pathway
France’s Looming Budget Crisis and Political Fracture Raise Fears of Becoming Europe’s “Sick Man”
Three Russian MiG-31 Jets Breach Estonian Airspace in ‘Unprecedentedly Brazen’ NATO Incident
European manufacturers against ban on polluting cars: "The industry may collapse"
Turkish car manufacturer Togg Enters German Market with 5-Star Electric Sedan and SUV to Challenge European EV Brands
Christian Brueckner Released from German Prison after Serving Unrelated Sentence
×